Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.

Saved in:
Bibliographic Details
Title: Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.
Authors: Abe K; Stanford University School of Medicine, Palo Alto, CA, United States., Holmes TH; Stanford University School of Medicine, Palo Alto, CA, United States., Nguyen TT; Stanford University School of Medicine, Palo Alto, CA, United States., Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, NY, United States., Levy O; Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Melamed E; The University of Texas at Austin, Austin, TX, United States., Ehrlich LIR; The University of Texas at Austin, Austin, TX, United States., McComsey GA; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, United States., Sekaly RP; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, United States., Cairns CB; Tower Health Hospital, Drexel University, Philadelphia, PA, United States., Haddad EK; Tower Health Hospital, Drexel University, Philadelphia, PA, United States., Shaw AC; Yale School of Medicine, New Haven, CT, United States., Hafler DA; Yale School of Medicine, New Haven, CT, United States., Montgomery RR; Yale School of Medicine, New Haven, CT, United States., Corry DB; Baylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX, United States., Kheradmand F; Baylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX, United States., Atkinson MA; University of Florida, Gainesville, FL, United States., Brakenridge SC; University of Florida, Gainesville, FL, United States., Agudelo Higuita NI; Oklahoma University Health Sciences Center, Oklahoma City, OK, United States., Metcalf JP; Oklahoma University Health Sciences Center, Oklahoma City, OK, United States., Hough CL; Oregon Health & Science University, Portland, OR, United States., Messer WB; Oregon Health & Science University, Portland, OR, United States., Pulendran B; Stanford University School of Medicine, Palo Alto, CA, United States., Nadeau KC; Stanford University School of Medicine, Palo Alto, CA, United States., Davis MM; Stanford University School of Medicine, Palo Alto, CA, United States., Fernandez-Sesma A; Icahn School of Medicine at Mount Sinai, New York, NY, United States., Simon V; Icahn School of Medicine at Mount Sinai, New York, NY, United States., Kraft M; University of Arizona, Tucson, AZ, United States., Bime C; University of Arizona, Tucson, AZ, United States., Calfee CS; University of California, San Francisco, San Francisco, CA, United States., Erle DJ; University of California, San Francisco, San Francisco, CA, United States., Schaenman J; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Reed EF; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Ozonoff A; Clinical and Data Coordinating Center, Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., Peters B; La Jolla Institute for Immunology, La Jolla, CA, United States., Kleinstein SH; Yale School of Medicine, New Haven, CT, United States., Augustine AD; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Diray-Arce J; Clinical and Data Coordinating Center, Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., Becker PM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Rouphael N; Emory School of Medicine, Atlanta, GA, United States., Maecker HT; Stanford University School of Medicine, Palo Alto, CA, United States.
Corporate Authors: IMPACC Network
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2025 Dec 01; Vol. 214 (12), pp. 3310-3320.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1550-6606
DOI:10.1093/jimmun/vkaf263